Ask AI
ProCE Banner Activity

Experts Discuss HCP Questions on CELMoD Agent Therapy for Multiple Myeloma

Clinical Thought

In this commentary, experts address key questions on CELMoD agent therapy for multiple myeloma, including a new approval, combination strategies, adverse event management, and potential use in extramedullary disease.

Released: August 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the impact of binding affinity and potency on the antimyeloma activity of individual novel agents and approaches

  • Evaluate the potential clinical implications of emerging data for novel therapies on treatment of multiple myeloma across the disease continuum

  • Identify patients with multiple myeloma who may be eligible for and likely to benefit from enrollment on clinical trials investigating novel therapies

Financial Disclosures

Primary Author

Sagar Lonial, MD, FACP, FASCO: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GSK, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; individual publicly traded stock/stock options: TG Therapeutics.

Fredrik Schjesvold, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Johnson & Johnson, Kite/Gilead, Menarini, Oncopeptides, Pfizer, Regeneron, Sanofi.

Niels van de Donk, MD, PhD: researcher: Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen, Novartis; advisor (paid to institution): AbbVie, Adaptive, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen, Kite, Merck, Novartis, Pfizer, Roche, Sanofi, Servier, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.